A large-scale study has revealed a surprising connection between medications commonly used to treat type 2 diabetes – including Ozempic and Mounjaro – and a potential reduction in the risk of developing substance employ disorders. The research, conducted among veterans of the U.S. Army, too suggests these drugs may lessen the severity of existing addictions. This finding adds to a growing body of evidence, initially observed in smaller studies, indicating a broader impact of these medications beyond blood sugar control.
The study, published in the British Medical Journal (BMJ), found a protective effect against a range of addictive substances and behaviors, including cocaine, opioids, alcohol, nicotine, and cannabis. Researchers were particularly struck by the breadth of this effect, as few treatments currently available demonstrate efficacy across multiple substances. Dr. Ziad Al-Aly, from the St. Louis VA Medical Center in Missouri, who led the study, noted the unexpected scope of the findings, stating, “In the field of addiction, you don’t have one drug that works with all of these substances.”
How GLP-1 Medications May Impact Addiction
The research team utilized data from the U.S. Department of Veterans Affairs to identify patients with type 2 diabetes treated with two distinct classes of medications. The first group received GLP-1 receptor agonists, such as Trulicity, Mounjaro (from Eli Lilly), Victoza, or Ozempic (from Novo Nordisk). The second group received sodium-glucose cotransporter 2 (SGLT2) inhibitors like Jardiance (Boehringer Ingelheim) and Farxiga (AstraZeneca). The groups were then compared using propensity score matching.
Importantly, most participants in the study were not receiving the high doses of GLP-1 medications often used for weight loss. The study focused on the impact of these drugs as prescribed for diabetes management.
Reduced Risk of Recent Substance Use Disorders
Among 124,001 participants without a prior history of substance use, those taking GLP-1 medications were 14% less likely to develop a new substance use disorder within the following three years, compared to 400,816 patients taking SGLT2 inhibitors. Specifically, GLP-1 medications were associated with an 18% reduction in new alcohol use disorders, a 14% reduction in cannabis use disorders, a 20% reduction in cocaine use disorders, a 26% reduction in nicotine use disorders, and a 25% reduction in opioid use disorders.
For the 81,617 patients already struggling with substance use disorders, GLP-1 medications were linked to a 31% decrease in emergency department visits over the three-year period. Hospitalizations were reduced by 26%, deaths related to substance use by 50%, overdose events by 39%, and suicidal ideation or attempts by 25%.
A Common Biological Pathway?
Dr. Al-Aly explained that current medical training emphasizes a targeted approach to addiction treatment – “If a patient is addicted to substance (A), you give them treatment for substance (A), like a nicotine patch for tobacco, or naltrexone for alcohol.” Though, he added, “Here we have this drug that works with all substances of addiction, and this tells us that there is likely a common biological pathway driving all of these forms of addiction, and that is treatable, or containable, by GLP-1.”
Researchers believe GLP-1 medications likely act on the “mesolimbic system,” reducing cravings by quieting the noise in the brain that drives overeating or drug seeking. The exact mechanisms are still being investigated.
The long-term effects of GLP-1 medications on addiction remain unknown. Researchers are currently exploring whether the benefits will persist with prolonged use and whether the brain may adapt, diminishing the effects of the drugs over time. “We are very interested in understanding this and trying to explore it further,” Dr. Al-Aly stated.
This research opens new avenues for understanding and potentially treating addiction, suggesting a shared neurological basis for various substance use disorders. While further investigation is needed to confirm these findings and determine optimal treatment strategies, the initial results offer a promising new perspective on addiction management.
The implications of this study are significant, potentially reshaping approaches to addiction treatment and prevention. Continued research will be crucial to fully understand the long-term effects and optimal applications of GLP-1 medications in addressing substance use disorders.
Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
